Physician profile
James T Soignet
NPI 1326037730
$2,217.43
in general payments reported to CMS, 2019-2025
35 companies · $399 in 2025
The $399 reported for 2025 was more than what 80% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $125 · 2021: $371 · 2022: $268 · 2023: $322 · 2024: $442 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $306.59 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Novo Nordisk INC | $192.44 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Glaxosmithkline, LLC. | $180.06 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $136.24 | 2021-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $128.74 | 2019-2025 | |
| Amgen INC. | $111.14 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $76.89 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $76.60 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.08 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $73.91 | 2019-2023 | Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $71.08 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $69.44 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.53 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $61.65 | 2021-2025 | Freestyle Libre |
| Novartis Pharmaceuticals Corporation | $59.77 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.15 | 2021-2023 | Trintellix |
| Sumitomo Pharma America, INC. | $49.13 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $47.79 | 2022-2025 | |
| Allergan, INC. | $46.27 | 2019-2020 | |
| Esperion Therapeutics, INC. | $42.81 | 2020-2023 | Nexletol |
| Ironshore Pharmaceuticals INC. | $35.14 | 2024 | |
| Dexcom, INC. | $29.56 | 2024 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $28.33 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $22.17 | 2024 | Auvelity |
| Adlon Therapeutics L.P. | $19.72 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.65 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $19.43 | 2025 | Zenpep |
| Cranial Technologies, INC | $18.09 | 2025 | Doc Band |
| Clarus Therapeutics INC. | $16.38 | 2021 | |
| Eisai INC. | $16.23 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.21 | 2023 | Rexulti |
| Shield Therapeutics INC | $14.53 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.18 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.78 | 2022 | |
| Astellas Pharma US INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Soignet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.